CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Axicabtagene ciloleucel 治疗原发性纵隔大 B 细胞淋巴瘤比弥漫性大 B 细胞淋巴瘤更有效：意大利 CART-SIE 研究
英文原题：Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
查看英文原题
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Axicabtagene ciloleucel对复发/难治性大B细胞淋巴瘤（LBCL）显示出疗效，包括原发性纵隔B细胞淋巴瘤（PMBCL）；然而，仅有少数PMBCL被报道。目的是在意大利前瞻性观察性CART-SIE研究中，评估axicabtagene ciloleucel在PMBCL患者中与其他LBCL患者相比的疗效和安全性。与其他LBCL（n = 190）相比，PMBCL（n = 70）更年轻，大包块和难治性疾病比例更高。输注患者的中位随访时间为12.17个月（IQR 5.53,22.73）。桥接后的总体（完全+部分）缓解率（ORR，CR + PR）在PMBCL中为41%，在其他LBCL中为28%，p = 0.0102。30天ORR在PMBCL中为78%（53/68），其中50%（34）为CR；在其他LBCL中为75%（141/187），其中53%（100）为CR，p = 0.5457。
90天ORR在PMBCL中为69%（45/65），其中65%（42）为CR；在其他LBCL中为54%（87/162），其中47%（76）为CR；疾病进展在PMBCL中为21%，在其他LBCL中为45%，p = 0.0336。12个月无进展生存率在PMBCL中为62%（95% CI：51-75），而在其他LBCL中为48%（95% CI：41-57），p = 0.0386。12个月总生存率在PMBCL中为86%（95% CI：78-95），而在其他LBCL中为71%（95% CI：64-79），p = 0.0034。所有级别细胞因子释放综合征为88%（228/260）；所有级别神经毒性为34%（88/260），其中PMBCL中致命事件为6%。非复发死亡率为3%。
总之，PMBCL相比其他LBCL取得了显著更好的缓解率和生存率。
展开英文摘要原文
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate efficacy and safety of axicabtagene ciloleucel in patients with PMBCL compared to those with other LBCL, enrolled in the Italian prospective observational CART-SIE study. PMBCLs (n = 70) were younger, with higher percentage of bulky and refractory disease, compared to other LBCLs (n = 190). Median follow-up time for infused patients was 12. 17 months (IQR 5. 53,22. 73). The overall (complete + partial) response rate (ORR,CR + PR) after bridging was 41% for PMBCL and 28% for other LBCL, p = 0. 0102.
Thirty days ORR was 78% (53/68) with 50% (34) CR in PMBCL, and 75% (141/187) with 53% (100) CR in other LBCL, p = 0. 5457. Ninety days ORR was 69% (45/65) with 65% (42) CR in PMBCL, and 54% (87/162) with 47% (76) CR in other LBCL; progressive disease was 21% in PMBCL and 45% in other LBCL, p = 0. 0336.
Twelve months progression-free survival was 62% (95% CI: 51-75) in PMBCL versus 48% (95% CI: 41-57) in other LBCL, p = 0. 0386. Twelve months overall survival was 86% (95% CI: 78-95) in PMBCL versus 71% (95% CI: 64-79) in other LBCL, p = 0. 0034. All grade cytokine release syndrome was 88% (228/260); all grade neurotoxicity was 34% (88/260), with 6% of fatal events in PMBCL. Non-relapse mortality was 3%.
In conclusion, PMBCLs achieved significantly better response and survival rates than other LBCLs.
论文信息
- 作者
- Chiappella A、Casadei B、Chiusolo P、Di Rocco A、Ljevar S、Magni M、Angelillo P、Barbui AM
- 单位
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. annalisa.chiappella@istitutotumori.mi.it.Italy
- 文献类型
- 非美国政府资助研究 · 观察性研究 · 多中心研究
- 期刊
- Leukemia2024 May
- 原文标识
- PubMed 38459167 · DOI 10.1038/s41375-024-02213-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →